Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.

Gonzalez FJ, Jiang C, Patterson AD.

Gastroenterology. 2016 Nov;151(5):845-859. doi: 10.1053/j.gastro.2016.08.057. Epub 2016 Sep 14. Review.

PMID:
27639801
2.

Mechanism of bile acid-regulated glucose and lipid metabolism in duodenal-jejunal bypass.

Chai J, Zou L, Li X, Han D, Wang S, Hu S, Guan J.

Int J Clin Exp Pathol. 2015 Dec 1;8(12):15778-85. eCollection 2015.

3.

Role of farnesoid X receptor and bile acids in alcoholic liver disease.

Manley S, Ding W.

Acta Pharm Sin B. 2015 Mar;5(2):158-67. doi: 10.1016/j.apsb.2014.12.011. Epub 2015 Mar 9. Review.

4.

Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration.

Li G, L Guo G.

Acta Pharm Sin B. 2015 Mar;5(2):93-8. doi: 10.1016/j.apsb.2015.01.005. Epub 2015 Feb 20. Review.

5.

Structure-based drug design targeting the cell membrane receptor GPBAR1: exploiting the bile acid scaffold towards selective agonism.

Di Leva FS, Festa C, Renga B, Sepe V, Novellino E, Fiorucci S, Zampella A, Limongelli V.

Sci Rep. 2015 Nov 16;5:16605. doi: 10.1038/srep16605.

6.

NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor.

Schmidt J, Klingler FM, Proschak E, Steinhilber D, Schubert-Zsilavecz M, Merk D.

Sci Rep. 2015 Oct 1;5:14782. doi: 10.1038/srep14782.

7.
8.

Deletion of mouse FXR gene disturbs multiple neurotransmitter systems and alters neurobehavior.

Huang F, Wang T, Lan Y, Yang L, Pan W, Zhu Y, Lv B, Wei Y, Shi H, Wu H, Zhang B, Wang J, Duan X, Hu Z, Wu X.

Front Behav Neurosci. 2015 Mar 30;9:70. doi: 10.3389/fnbeh.2015.00070. eCollection 2015.

9.

Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis.

Jiao Y, Lu Y, Li XY.

Acta Pharmacol Sin. 2015 Jan;36(1):44-50. doi: 10.1038/aps.2014.116. Epub 2014 Dec 15. Review.

10.

FXR and liver carcinogenesis.

Huang XF, Zhao WY, Huang WD.

Acta Pharmacol Sin. 2015 Jan;36(1):37-43. doi: 10.1038/aps.2014.117. Epub 2014 Dec 15. Review.

11.

Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes.

Ding L, Pang S, Sun Y, Tian Y, Yu L, Dang N.

Int J Endocrinol. 2014;2014:751859. doi: 10.1155/2014/751859. Epub 2014 Apr 28. Review.

12.

Synthetic FXR agonist GW4064 is a modulator of multiple G protein-coupled receptors.

Singh N, Yadav M, Singh AK, Kumar H, Dwivedi SK, Mishra JS, Gurjar A, Manhas A, Chandra S, Yadav PN, Jagavelu K, Siddiqi MI, Trivedi AK, Chattopadhyay N, Sanyal S.

Mol Endocrinol. 2014 May;28(5):659-73. doi: 10.1210/me.2013-1353. Epub 2014 Mar 5.

13.
14.

Mechanisms of STAT3 activation in the liver of FXR knockout mice.

Li G, Zhu Y, Tawfik O, Kong B, Williams JA, Zhan L, Kassel KM, Luyendyk JP, Wang L, Guo GL.

Am J Physiol Gastrointest Liver Physiol. 2013 Dec;305(11):G829-37. doi: 10.1152/ajpgi.00155.2013. Epub 2013 Oct 3.

15.

Poly(ADP-ribose) polymerase 1 promotes oxidative-stress-induced liver cell death via suppressing farnesoid X receptor α.

Wang C, Zhang F, Wang L, Zhang Y, Li X, Huang K, Du M, Liu F, Huang S, Guan Y, Huang D, Huang K.

Mol Cell Biol. 2013 Nov;33(22):4492-503. doi: 10.1128/MCB.00160-13. Epub 2013 Sep 16.

16.

Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.

Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Böttger J, Braeuning A, Budinsky RA, Burkhardt B, Cameron NR, Camussi G, Cho CS, Choi YJ, Craig Rowlands J, Dahmen U, Damm G, Dirsch O, Donato MT, Dong J, Dooley S, Drasdo D, Eakins R, Ferreira KS, Fonsato V, Fraczek J, Gebhardt R, Gibson A, Glanemann M, Goldring CE, Gómez-Lechón MJ, Groothuis GM, Gustavsson L, Guyot C, Hallifax D, Hammad S, Hayward A, Häussinger D, Hellerbrand C, Hewitt P, Hoehme S, Holzhütter HG, Houston JB, Hrach J, Ito K, Jaeschke H, Keitel V, Kelm JM, Kevin Park B, Kordes C, Kullak-Ublick GA, LeCluyse EL, Lu P, Luebke-Wheeler J, Lutz A, Maltman DJ, Matz-Soja M, McMullen P, Merfort I, Messner S, Meyer C, Mwinyi J, Naisbitt DJ, Nussler AK, Olinga P, Pampaloni F, Pi J, Pluta L, Przyborski SA, Ramachandran A, Rogiers V, Rowe C, Schelcher C, Schmich K, Schwarz M, Singh B, Stelzer EH, Stieger B, Stöber R, Sugiyama Y, Tetta C, Thasler WE, Vanhaecke T, Vinken M, Weiss TS, Widera A, Woods CG, Xu JJ, Yarborough KM, Hengstler JG.

Arch Toxicol. 2013 Aug;87(8):1315-530. doi: 10.1007/s00204-013-1078-5. Epub 2013 Aug 23. Review.

17.

Pleiotropic roles of bile acids in metabolism.

de Aguiar Vallim TQ, Tarling EJ, Edwards PA.

Cell Metab. 2013 May 7;17(5):657-69. doi: 10.1016/j.cmet.2013.03.013. Epub 2013 Apr 18. Review.

18.

Nuclear receptors as drug targets in cholestatic liver diseases.

Halilbasic E, Baghdasaryan A, Trauner M.

Clin Liver Dis. 2013 May;17(2):161-89. doi: 10.1016/j.cld.2012.12.001. Review.

19.

Hepatocyte nuclear factor 4 alpha and farnesoid X receptor co-regulates gene transcription in mouse livers on a genome-wide scale.

Thomas AM, Hart SN, Li G, Lu H, Fang Y, Fang J, Zhong XB, Guo GL.

Pharm Res. 2013 Sep;30(9):2188-98. doi: 10.1007/s11095-013-1006-7. Epub 2013 Mar 6.

20.

Plant sterols as anticancer nutrients: evidence for their role in breast cancer.

Grattan BJ Jr.

Nutrients. 2013 Jan 31;5(2):359-87. doi: 10.3390/nu5020359. Review.

Supplemental Content

Support Center